The results of our own studies with CD38-specific nanobodies illustrate the utility of nanobody-based heavy chain antibodies, BiKEs, CARs and nanobody-displaying AAV vectors to specifically and effectively target CD38-expressing myeloma cells. This evidence concerns the gene CD38 and plasma cell myeloma.